RED ND: YAG LASER FOR PHOTODYNAMIC THERAPY

RED ND：用于光动力治疗的 YAG 激光

• 批准号: 3506694
• 负责人: DANIEL R DOIRON
• 金额: $ 31.15万
• 依托单位: PDT SYSTEMS
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-09-30 至 1992-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3506694
• 关键词: biomedical equipment development; clinical biomedical equipment; laboratory mouse; laser therapy; lasers

Photodynamic therapy (PDT) is continuing to undergo a rapid expansion in basic, preclinical and clinical research, and development as a modality for the diagnosis and treatment of cancer and other nonmalignant diseases. One of the major hindrances to this development is the lack of an efficient, reliable and easy to use laser source. In addition, a great deal of development is presently underway on 2nd generation photosensitizers, PSS, with absorption deeper in the red and near infrared spectra, <1200 nm. In phase-I a red Nd:YAG laser, 659nm, was developed and tested in combination with a 2nd generation PSS in a mouse tumor model. The laser is a KTP doubled 1318nm Nd:YAG and the photosensitizer the tin-IV etiopurpurin dichloride, SnET2. Animal testing of this combination of drug and laser determined it to be a viable PDT package. In phase-II it is the objective to further develop and refine the 659nm laser and quantitate its performance with three 2nd generation PSS. This will include the conversion of an existing clinical 532nm doubled Nd:YAG laser system to 659nm operation and its expanded testing with SnET2. Additionally, testing with the aspartyl-chlorin-E6. NP-6 PSS will be done. This testing will include direct comparison to the CW argon pumped dye laser to evaluate the impact of the 659nm ND: YAG's pulsed nature. Based on the results of the animal studies and the availability of the new 2nd generation PSS for clinical studies, limited phase-I clinical trials of the 659nm laser may be undertaken in the second year of the phase-II program. This PDT system package could provide a significant improvement in both the effectiveness and useability of PDT.

光动力学疗法（PDT）正在继续经历快速扩张， 基础、临床前和临床研究，以及作为 癌症和其他非恶性疾病的诊断和治疗。 一 这一发展的主要障碍之一是缺乏一个有效的， 可靠且易于使用的激光源。 此外，大量的 目前正在开发第二代光敏剂，PSS， 在<1200 nm的红色和近红外光谱中具有更深的吸收。 在 研制了659 nm的Nd：YAG Ⅰ相红光激光器，并进行了组合测试 与第二代PSS在小鼠肿瘤模型中进行比较。 激光器是KTP 双1318 nm Nd：YAG和光敏剂Tin-Ⅳ紫嘌呤 二氯化物，SnET 2。 这种药物和激光组合的动物试验 确定它是可行的PDT包。 第二阶段的目标是 进一步发展和完善659纳米激光，并量化其 三个第二代PSS。 这将包括 将现有临床532 nm倍频Nd：YAG激光系统转换为 659 nm操作及其SnET 2扩展测试。 此外，测试 用的是乙酰氯E6将完成NP-6 PSS。 本试验将 包括与连续波氩泵浦染料激光器的直接比较， 659 nm ND：YAG的脉冲特性的影响。 的结果基础上 动物研究和新的第二代PSS的可用性， 临床研究，659 nm激光的有限I期临床试验可能是 在第二阶段计划的第二年进行。 这个PDT系统 一揽子计划可以显着提高有效性 和PDT的可用性。